Adherence to Secondary Prophylaxis Among Patients with Acute Rheumatic Fever and Rheumatic Heart Disease

Author(s): John A. Woods*, Judith M. Katzenellenbogen.

Journal Name: Current Cardiology Reviews

Volume 15 , Issue 3 , 2019

Become EABM
Become Reviewer

[1]
Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med 2017; 377: 713-22.
[2]
Vongprateep C, Dharmasakti D, Sindhavanonda K. The national programme and the control of rheumatic fever and rheumatic heart disease in two project areas of Thailand. N Z Med J 1988; 101: 408-10.
[3]
World Health Organization. Rheumatic fever and rheumatic heart disease–Report by the Director-General (Seventy-First World Health Assembly Provisional agenda item 128–A71/25). Geneva: WHO 2018.
[4]
Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers 2016; 2: 15084.
[5]
Irlam JH, Mayosi BM, Engel ME, Gaziano TA. A cost-effective strategy for primary prevention of acute rheumatic fever and rheumatic heart disease in children with pharyngitis. S Afr Med J 2013; 103: 894-5.
[6]
Wyber R, Boyd BJ, Colquhoun S, et al. Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. Drug Deliv Transl Res 2016; 6: 572-8.
[7]
WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease. Rheumatic fever and rheumatic heart disease: Report of a WHO Expert Consultation, Geneva, October 29– November 1, 2001 WHO Technical Report Series; 923. Geneva: World Health Organization. 2004.
[8]
Lawrence JG, Carapetis JR, Griffiths K, Edwards K, Condon JR. Acute rheumatic fever and rheumatic heart disease: Incidence and progression in the Northern Territory of Australia, 1997 to 2010. Circulation 2013; 128: 492-501.
[9]
Osowicki J, Vekemans J, Kaslow DC, Friede MH, Kim JH, Steer AC. WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016. Vaccine 2018; 36: 3397-405.
[10]
Kevat PM, Reeves BM, Ruben AR, Gunnarsson R. Adherence to secondary prophylaxis for acute rheumatic fever and rheumatic heart disease: A systematic review. Curr Cardiol Rev 2017; 13(2): 155-66.
[11]
de Dassel JL, Fittock MT, Wilks SC, Poole JE, Carapetis JR, Ralph AP. Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data. PLoS One 2017; 12: e0178264.
[12]
Read C, Mitchell AG, de Dassel JL, et al. Qualitative evaluation of a complex intervention to improve rheumatic heart disease secondary prophylaxis. J Am Heart Assoc 2018; 7: e009376.
[13]
Ralph AP, de Dassel JL, Kirby A, et al. Improving delivery of secondary prophylaxis for rheumatic heart disease in a high‐burden setting: Outcome of a stepped‐wedge, community, randomized trial. J Am Heart Assoc 2018; 7: e009308.
[14]
Balbaa A, ElGuindy A, Pericak D, Yacoub MH, Schwalm JD. An evaluation of secondary prophylaxis for rheumatic heart disease in rural Egypt. Glob Cardiol Sci Pract 2015; 2015: 40.
[15]
Engelman D, Ah Kee M, Mataika RL, et al. Secondary prevention for screening detected rheumatic heart disease: opportunities to improve adherence. Trans R Soc Trop Med Hyg 2017; 111: 154-62.
[16]
Engelman D, Mataika RL, Kado JH, et al. Adherence to secondary antibiotic prophylaxis for patients with rheumatic heart disease diagnosed through screening in Fiji. Trop Med Int Health 2016; 21: 1583-91.
[17]
Mehta A, Saxena A, Juneja R, Ramakrishnan S, Gupta S, Kothari SS. Characteristics and outcomes of Indian children enrolled in a rheumatic heart disease registry. Int J Cardiol 2016; 222: 1136-40.
[18]
Thompson SB, Brown CH, Edwards AM, Lindo JL. Low adherence to secondary prophylaxis among clients diagnosed with rheumatic fever, Jamaica. Pathog Glob Health 2014; 108: 229-34.
[19]
Barker H, Oetzel JG, Scott N, Morley M, Carr PEA, Oetzel KB. Enablers and barriers to secondary prophylaxis for rheumatic fever among Maori aged 14-21 in New Zealand: A framework method study. Int J Equity Health 2017; 16: 201.
[20]
Culliford-Semmens N, Tilton E, Webb R, et al. Adequate adherence to benzathine penicillin secondary prophylaxis following the diagnosis of rheumatic heart disease by echocardiographic screening. N Z Med J 2017; 130: 5057.
[21]
Huck DM, Nalubwama H, Longenecker CT, Frank SH, Okello E, Webel AR. A qualitative examination of secondary prophylaxis in rheumatic heart disease: Factors influencing adherence to secondary prophylaxis in Uganda. Glob Hear. 2015 10: 63-9 e61.
[22]
Long A, Lungu JC, Machila E, et al. A programme to increase appropriate usage of benzathine penicillin for management of streptococcal pharyngitis and rheumatic heart disease in Zambia. Cardiovasc J Afr 2017; 28: 242-7.
[23]
Mincham CM, Toussaint S, Mak DB, Plant AJ. Patient views on the management of rheumatic fever and rheumatic heart disease in the Kimberley: A qualitative study. Aust J Rural Health 2003; 11: 260-5.
[24]
Kumar R, Thakur JS, Aggarwal A, Ganguly NK. Compliance of secondary prophylaxis for controlling rheumatic fever and rheumatic heart disease in a rural area of northern India. Indian Heart J 1997; 49: 282-8.
[25]
Harrington Z, Thomas DP, Currie BJ, Bulkanhawuy J. Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community. Med J Aust 2006; 184: 514-7.
[26]
Grayson S, Horsburgh M, Lennon D. An Auckland regional audit of the nurse-led rheumatic fever secondary prophylaxis programme. N Z Med J 2006; 119: U2255.
[27]
Bassili A, Zaher SR, Zaki A, Abdel-Fattah M, Tognoni G. Profile of secondary prophylaxis among children with rheumatic heart disease in Alexandria, Egypt. East Mediterr Health J 2000; 6: 437-46.
[28]
Kumar R, Raizada A, Aggarwal AK, Ganguly NK. A community-based rheumatic fever/rheumatic heart disease cohort: Twelve-year experience. Indian Heart J 2002; 54: 54-8.
[29]
Eissa S, Lee R, Binns P, Garstone G, McDonald M. Assessment of a register-based rheumatic heart disease secondary prevention program in an Australian Aboriginal community. Aust N Z J Public Health 2005; 29: 521-5.
[30]
Rémond MGW, Severin KL, Hodder Y, et al. Variability in disease burden and management of rheumatic fever and rheumatic heart disease in two regions of tropical Australia. Int Med J 2013; 43: 386-93.
[31]
de Dassel JL, Ralph AP, Carapetis JR. Controlling acute rheumatic fever and rheumatic heart disease in developing countries: Are we getting closer? Curr Opin Pediatr 2015; 27: 116-23.
[32]
Wyber R. Rheumatic heart disease: Tools for implementing programmes. Glob Heart 2015; 10: 79-80.
[33]
Levesque JF, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int J Equity Health 2013; 12: 18.
[34]
Mitchell AG, Belton S, Johnston V, Ralph AP. Transition to adult care for Aboriginal children with rheumatic fever: A review informed by a focussed ethnography in northern Australia. Aust J Prim Health 2018; 24: 9-13.
[35]
Montagnat OD, Webster GR, Bulitta JB, et al. Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD). Drug Deliv Transl Res 2018; 8: 729-39.
[36]
RHDAustralia. Treatment Tracker App; 2018. https://www.rhdaustralia.org.au/treatment-tracker-app Accessed 18 Jul 2018.
[37]
Manji RA, Witt J, Tappia PS, Jung Y, Menkis AH, Ramjiawan B. Cost-effectiveness analysis of rheumatic heart disease prevention strategies. Expert Rev Pharmacoecon Outcomes Res 2013; 13: 715-24.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2019
Page: [239 - 241]
Pages: 3
DOI: 10.2174/1573403X1503190506120953

Article Metrics

PDF: 45
HTML: 5
PRC: 1